Groupe D'etude Therapeutique Des Affections Inflammatoires Digestives
Clinical trials sponsored by Groupe D'etude Therapeutique Des Affections Inflammatoires Digestives, explained in plain language.
-
Can a higher dose of upadacitinib rescue ulcerative colitis patients when standard treatment fails?
Disease control Not yet recruitingThis study tests whether a temporary higher dose of upadacitinib (45 mg daily) can bring ulcerative colitis back under control in adults whose disease flared up while on the standard 30 mg maintenance dose. Participants receive the higher dose for 8 to 16 weeks, then may step dow…
Phase: PHASE4 • Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can better detection of precancerous lesions in IBD prevent colorectal cancer?
Knowledge-focused Not yet recruitingPeople with inflammatory bowel disease (Crohn's disease or ulcerative colitis) have a higher risk of developing colorectal cancer. This study follows 800 adults with IBD who need a screening colonoscopy to look for precancerous growths called dysplasia. Researchers aim to underst…
Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC